The Suraksha Clinic and Diagnostic IPO has been structured as a book-built issue of ₹846.25 crores. The entire issue consists of an offer for sale of 1.92 crore shares.
The IPO is scheduled to be opened for subscription on November 29, 2024, and will remain open until December 3, 2024. The allotment of shares is expected to be finalized by Wednesday, December 4, 2024. The listing of the IPO will take place on the BSE and NSE, with the tentative date set as Friday, December 6, 2024.
The price band for the Suraksha Clinic and Diagnostic IPO has been set between ₹420 and ₹441 per share. A minimum of 34 shares is required for a single application. Retail investors are required to invest a minimum amount of ₹14,994. For sNII investors, a minimum investment of 14 lots (476 shares) is required, amounting to ₹209,916. For bNII investors, the minimum investment is set at 67 lots (2,278 shares), totaling ₹1,004,598.
Get the Suraksha Clinic and Diagnostic IPO RHP for detailed information.
| IPO Date | November 29, 2024 to December 3, 2024 |
| Listing Date | December 6, 2024 |
| Face Value | ₹ 2 / Share |
| Price Band | ₹ 420 to ₹ 441 / Share |
| Lot Size | 34 Shares |
| Total Issue Size | ₹846.25 Cr |
| Fresh Issue | |
| Offer for Sale | ₹846.25 Cr |
| Employee Discount | |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 52,080,758 |
| Share holding post issue | |
| Market Maker portion |
Suraksha Diagnostic Limited IPO opens on November 29, 2024, and closes on December 3, 2024.
| IPO Open Date | November 29, 2024 |
| IPO Close Date | December 3, 2024 |
| Basis of Allotment | December 4, 2024 |
| Initiation of Refunds | December 5, 2024 |
| Credit of Shares to Demat | December 5, 2024 |
| Listing Date | December 6, 2024 |
| Cut-off time for UPI mandate confirmation | December 3, 2024 |
The bidding for the IPO can be done by investors for a minimum of 34 shares and in multiples thereafter. The table below illustrates the minimum and maximum investments required by retail investors and HNIs in terms of both shares and the corresponding amounts.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 34 | Rs.14,994 |
| Retail (Max) | 13 | 442 | Rs.194,922 |
| S-HNI (Min) | 14 | 476 | Rs.209,916 |
| S-HNI (Max) | 66 | 2,244 | Rs.989,604 |
| B-HNI (Min) | 67 | 2,278 | Rs.1,004,598 |
| HNI (Min) |
| Share Holding Pre Issue | 61.07% |
| Share Holding Post Issue |
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | |
|
| Market Maker Shares Offered | |
|
| Other Shares Offered | |
|
| QIB Shares Offered | Not more than 50% of the Net Offer |
|
| NII (HNI) Shares Offered | Not less than 15% of the Net Offer |
|
| bNII > ₹10L | |
|
| sNII < ₹10L | |
|
| Retail Shares Offered | Not less than 35% of the Net Offer |
|
| Employee Shares Offered | |
|
| Total Shares Offered | |
| Bid Date | |
| Shares Offered | |
| Anchor Portion Size (In Cr.) | |
| Anchor lock-in period end date for 50% shares (30 Days) | |
| Anchor lock-in period end date for remaining shares (90 Days) |
Suraksha Diagnostic Limited, incorporated in 2005, is engaged in providing pathology, radiology testing, and medical consultancy services. As of June 30, 2024, the company’s operations are supported by a central reference laboratory, 8 satellite laboratories, and 215 customer touchpoints, which include 49 diagnostic centres and 166 sample collection centres across West Bengal, Bihar, Assam, and Meghalaya.
Medical consultation services, both online and offline, are offered under a single roof at 44 diagnostic centres, which also house 120 polyclinics staffed by over 750 doctors.
The operations of the diagnostic centres are streamlined using advanced technology platforms such as a Laboratory Information Management System (LIMS), a fully integrated Radiology Information System (RIS), a Picture Archive Communication System (PACS), and an Enterprise Resource Planning System (ERP).
Vaccination services and customized testing packages for disease prediction and early detection are also provided. Digital pathology and artificial intelligence are utilized for generating blood test results, while radiology reporting is facilitated through a digital platform. This platform enables cases to be reported from any diagnostic centre, significantly reducing turnaround times.
Competitive Strengths are:
| KPI | Values |
|---|---|
| ROE | 14.09% |
| ROCE | 21.46% |
| Debt/Equity | 0.2 |
| RoNW | 14.09% |
| P/BV | 13.1 |
| PAT Margin (%) | 10.57 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 4.44 | |
| P/E (x) | 99.31 |
Suraksha Diagnostic Limited Plot No. DG-12/1 Action Area 1D, Premises No. 02-0327 New Town, Rajarhat Kolkata 700 156 Phone: 91 33 66059750 Email: investors@surakshanet.com Website: https://www.surakshanet.com/ |
Kfin Technologies Limited Phone: 04067162222, 04079611000 Email: sdl.ipo@kfintech.com |
Lamfindia specializes in offering innovative financial solutions, including stock broker services, mutual fund investments, and IPO guidance.